Evidence map›Paper›PMID 30637718›Full record

ArticleThe British journal of dermatology2019

Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus.

M E Ogunsanya, S K Cho, A Hudson, B F Chong

Erratum issuedAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. The Possible Relation ofIranian journal of parasitology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

M E OgunsanyaCollege of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73117, U.S.A.ORCID 0000-0002-4005-0446
S K ChoDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, U.S.A.
A HudsonDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, U.S.A.
B F ChongDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, U.S.A.ORCID 0000-0002-4092-7658

Funding

Molecular Markers in Discoid Lupus ErythematousK23AR061441 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI CHONG, BENJAMIN FRANKLIN · 2012 to 2016
$653k
NIAMS NIH HHS K23 AR061441
6 · The paper itself

Abstract

backgroundCutaneous lupus erythematosus (CLE) is a potentially disfiguring, chronic autoimmune disease with variable skin manifestations, negatively affecting patients' quality of life (QoL). Patient-reported outcome (PRO) measures assessing QoL in patients with CLE have been generic or developed without input from patients.

objectivesTo demonstrate the reliability and validity of a disease-specific QoL measure for CLE - the cutaneous lupus erythematosus quality of life (CLEQoL).

methodsOne hundred and one patients with CLE were recruited, and each patient was asked to complete the CLEQoL. Internal consistency was used as a measure of reliability. Validity was measured in two ways - structural validity via exploratory factor analysis and convergent validity via Spearman correlations between CLEQoL and the Short Form 36 (SF-36), visual analogue scales and clinical variables. Patient demographic and disease characteristics were collected.

resultsThe mean ± SD age of patients with CLE was 48 ± 13 years, with discoid lupus (n = 72; 71.3%) being the most predominant CLE subtype. Patients were mostly female (n = 88; 87·1%) and African American/Black (n = 59; 58·4%). Internal consistency ranged from 0·67 to 0·97. Five domains (functioning, emotions, symptoms, body image/cosmetic effects and photosensitivity) were extracted with a total explained variance of 71·1%. CLEQoL-related domains correlated with SF-36 domains (r range -0·39 to -0·65).

conclusionsThe CLEQoL was found to be a valid and reliable PRO measure for assessing QoL in patients with CLE. Demonstrating that the CLEQoL has strong psychometric properties is an important step towards the development of a disease-specific PRO measure that future clinical trials can use.

Indexed as

Patient Reported Outcome MeasuresQuality of LifeSurveys and QuestionnairesAdultFemaleHumansLupus Erythematosus, CutaneousMaleMiddle AgedPsychometricsReproducibility of Results

Identifiers

PMID30637718
PMCPMC6546517

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.